Reuters logo
AstraZeneca returns several compounds to Targacept
February 10, 2014 / 10:16 PM / 4 years ago

AstraZeneca returns several compounds to Targacept

(Reuters) - Biotech company Targacept Inc TRGT.O said British drugmaker AstraZeneca (AZN.L) would return rights to several pre-clinical compounds, sending the U.S. company’s shares down 10 percent in extended trading.

A licensing agreement, signed in 2005, continues for the remaining compounds, including AZD1446, a potential treatment for Alzheimer’s disease.

The amendment to the agreement becomes effective 90 days after February 7, Targacept said in a filing with the U.S. Securities and Exchange Commission. (

Targacept shares closed at $4.96 on the Nasdaq on Monday.

Reporting by Shailesh Kuber; Editing by Don Sebastian

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below